Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks

Charles P. Raines, Charles Flexner, Eugene Sun, Margo Heath-Chiozzi, Ronald H. Lewis, Cathy Fields, Carl Deetz, Linda Apuzzo, Susan H. Eshleman, J. Brooks Jackson, Joel E. Gallant

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Objective: To evaluate the safety, tolerability, and anti-HIV activity of ritonavirnelfinavir (RTV-NFV). Design: Single-site, open-label, nonrandomized, multiple-dose trial of RTV combined with two doses of NFV in protease inhibitor (PI)-naive, HIV-infected patients. Methods: Mean baseline HIV RNA was 39,500 copies/ml; mean baseline CD4 count was 323 cells/mm3. All patients received RTV at a dosage of 400 mg twice daily. Cohorts I (N = 10) and II (N = 10) received NFV at a dosage of 500 mg and 750 mg twice daily, respectively, for the initial 12 weeks of the study before allowing ,intensification with reverse transcriptase inhibitors. Results: The commonest effects of RTV-NFV therapy were study drug-related moderate-to-severe diarrhea (9 patients in cohorts I and II) and drug-related moderate-to-severe nausea (4 patients in cohorts I and II). HIV RNA was suppressed in a biphasic manner. At 48 weeks in cohort I, mean HIV RNA reduction was 2.82 log10 copies/ml (standard error [SE] = .61; p = .001; N = 4); mean CD4 cell count increase was 236 cells/mm3 (SE = 67.1; p = .006; N = 4). In cohort II, mean HIV RNA reduction at Week 48 was 2.21 log10 copies/ml (SE = .430; p = .001; N = 8); mean CD4 cell count increase was 120 cells/mm3 (SE = 47.5; p = .03; n = 8). In cohort I patients, 2 of 4 completing Week 48 had HIV RNA <20 copies/ml; and 3 of 4 had HIV RNA <400 copies/ml. In cohort II, 2 of 8 patients completing Week 48 had HIV RNA <20 copies/ml and 4 of 8 had HIV RNA <400 copies/ml. In addition, 3 patients in cohort I withdrew because of virologic failure not thought to be related to poor compliance. Moreover, 15 patients elected to add new reverse-transcriptase inhibitors (RTIs) after week 12. Conclusions: RTV-NFV with concomitant reverse transcriptase inhibitors is a potential dual-PI option for PI-naive patients.

Original languageEnglish (US)
Pages (from-to)322-328
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes
Volume25
Issue number4
DOIs
StatePublished - Dec 1 2000

Keywords

  • Antiretroviral therapy
  • Combination therapy
  • Protease inhibitors

Fingerprint Dive into the research topics of 'Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks'. Together they form a unique fingerprint.

  • Cite this

    Raines, C. P., Flexner, C., Sun, E., Heath-Chiozzi, M., Lewis, R. H., Fields, C., Deetz, C., Apuzzo, L., Eshleman, S. H., Jackson, J. B., & Gallant, J. E. (2000). Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. Journal of Acquired Immune Deficiency Syndromes, 25(4), 322-328. https://doi.org/10.1097/00126334-200012010-00005